Name | Number of supported studies | Average coverage | |
---|---|---|---|
non-classical monocyte | 18 studies | 39% ± 16% | |
conventional dendritic cell | 5 studies | 20% ± 4% | |
microglial cell | 5 studies | 23% ± 6% | |
myeloid cell | 4 studies | 23% ± 7% | |
macrophage | 4 studies | 28% ± 6% | |
monocyte | 3 studies | 20% ± 1% | |
mononuclear phagocyte | 3 studies | 28% ± 14% | |
memory B cell | 3 studies | 19% ± 1% | |
B cell | 3 studies | 18% ± 1% | |
dendritic cell | 3 studies | 28% ± 9% |
Insufficient scRNA-seq data for expression of SIGLEC10 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 96% | 1514.63 | 556 / 578 | 86% | 7.87 | 999 / 1155 |
brain | 60% | 268.37 | 1595 / 2642 | 99% | 20.48 | 696 / 705 |
adrenal gland | 97% | 1105.50 | 249 / 258 | 39% | 1.69 | 90 / 230 |
intestine | 65% | 634.18 | 629 / 966 | 70% | 5.16 | 368 / 527 |
prostate | 81% | 586.27 | 199 / 245 | 54% | 2.14 | 269 / 502 |
breast | 48% | 184.27 | 219 / 459 | 87% | 5.74 | 970 / 1118 |
bladder | 67% | 363.95 | 14 / 21 | 60% | 4.79 | 304 / 504 |
stomach | 53% | 202.24 | 190 / 359 | 74% | 6.33 | 211 / 286 |
pancreas | 44% | 173.36 | 144 / 328 | 80% | 7.91 | 143 / 178 |
kidney | 40% | 244.21 | 36 / 89 | 83% | 8.18 | 748 / 901 |
esophagus | 41% | 158.52 | 596 / 1445 | 66% | 3.85 | 120 / 183 |
lymph node | 0% | 0 | 0 / 0 | 100% | 66.62 | 29 / 29 |
spleen | 100% | 6870.17 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5360.03 | 928 / 929 | 0% | 0 | 0 / 0 |
uterus | 35% | 103.11 | 59 / 170 | 62% | 4.30 | 286 / 459 |
thymus | 42% | 162.35 | 271 / 653 | 49% | 3.39 | 296 / 605 |
tonsil | 0% | 0 | 0 / 0 | 89% | 9.32 | 40 / 45 |
ovary | 20% | 44.91 | 36 / 180 | 58% | 3.43 | 248 / 430 |
liver | 47% | 248.06 | 107 / 226 | 28% | 1.56 | 112 / 406 |
skin | 10% | 23.88 | 184 / 1809 | 61% | 6.04 | 289 / 472 |
blood vessel | 47% | 237.52 | 621 / 1335 | 0% | 0 | 0 / 0 |
adipose | 38% | 159.22 | 455 / 1204 | 0% | 0 | 0 / 0 |
heart | 28% | 102.93 | 242 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 24% | 1.26 | 19 / 80 |
muscle | 1% | 2.19 | 5 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0106015 | Biological process | negative regulation of inflammatory response to wounding |
GO_0007155 | Biological process | cell adhesion |
GO_0045087 | Biological process | innate immune response |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0042169 | Molecular function | SH2 domain binding |
GO_0019902 | Molecular function | phosphatase binding |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
GO_0033691 | Molecular function | sialic acid binding |
Gene name | SIGLEC10 |
Protein name | Sialic acid-binding Ig-like lectin 10 (Siglec-10) (Siglec-like protein 2) SIGLEC10 protein Sialic acid binding Ig like lectin 10 |
Synonyms | SLG2 UNQ477/PRO940 |
Description | FUNCTION: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid (By similarity). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, seems to act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules . Involved in negative regulation of B-cell antigen receptor signaling. The inhibition of B cell activation is dependent on PTPN6/SHP-1 (By similarity). In association with CD24 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90 (By similarity). In association with CD24 may regulate the immune repsonse of natural killer (NK) cells . Plays a role in the control of autoimmunity (By similarity). During initiation of adaptive immune responses by CD8-alpha(+) dendritic cells inhibits cross-presentation by impairing the formation of MHC class I-peptide complexes. The function seems to implicate recruitment of PTPN6/SHP-1, which dephosphorylates NCF1 of the NADPH oxidase complex consequently promoting phagosomal acidification (By similarity). . |
Accessions | ENST00000353836.9 [Q96LC7-2] ENST00000339313.10 [Q96LC7-1] E9PJA1 ENST00000442846.7 [Q96LC7-8] E9PL79 ENST00000436984.6 [Q96LC7-7] ENST00000439889.6 [Q96LC7-3] B7ZL04 B7ZL06 Q96LC7 ENST00000530476.1 ENST00000529627.1 ENST00000525998.5 ENST00000441969.7 [Q96LC7-6] E9PKV9 |